Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:brand |
gptkb:Tepezza
|
| gptkbp:CASNumber |
1418199-40-9
|
| gptkbp:developer |
gptkb:Horizon_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
teprotumumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:IgG1_kappa
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
hearing impairment
nausea diarrhea fatigue alopecia muscle spasm |
| gptkbp:target |
gptkb:insulin-like_growth_factor_1_receptor
|
| gptkbp:UNII |
6Z5F2A6E1T
|
| gptkbp:usedFor |
thyroid eye disease
|
| gptkbp:bfsParent |
gptkb:Tepezza
|
| gptkbp:bfsLayer |
8
|